Netherlands· NL-2eb90e911433

ZYNYZ 500 mg concentraat voor oplossing voor infusie

A retifanlimab product containing retifanlimab, registered in Netherlands by Incyte Biosciences Distribution B.V.. The same ATC class is registered in 10 of our 19 countries.

ATC L01FF10

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about retifanlimabAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Retifanlimab is registered in 10 of 19 countries.

Countries holding a registration under ATC L01FF10 (retifanlimab), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
7 of them publish a price we can compare per daily dose

Search retifanlimab products by name

Retifanlimab · ATC L01FF10

10 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Netherlands
Polandprice
Switzerlandprice
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: RETIFANLIMAB
Manufacturer: Incyte Biosciences Distribution B.V.
Country: Netherlands (NL)
ATC code: L01FF10
ATC class: Retifanlimab
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/24/1800

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Retifanlimab in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All retifanlimab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Zynyz
Liechtenstein · Zynyz
Norway · Zynyz

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/fc0a5b1b-411c-4a65-9f0e-0fd7cc09c67d
GET /v1/drugs/fc0a5b1b-411c-4a65-9f0e-0fd7cc09c67d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/zynyz-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Retifanlimab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp131245",
  "excipients": [
    "AZIJNZUUR (E 260), GECONCENTREERD",
    "NATRIUMACETAAT 3-WATER (E 262)",
    "POLYSORBAAT 80 (E 433)",
    "SACCHAROSE",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "RETIFANLIMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/04/19",
  "procedure_number": "EMEA/H/C/006194",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/24/1800",
  "additional_monitoring": "Y"
}

API reference MCP server Plans

See everything about retifanlimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console